Trial Profile
A Phase I, Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary) ; Elgemtumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 08 Jul 2021 Status changed from active, no longer recruiting to completed.
- 01 Jul 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.
- 01 Jul 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2022.